PRESS RELEASE: “NEGLIGENT” TO IGNORE: TGA Advisory Chair Warned of Heart Disease Breakthrough in 2022, Yet Agency Moves to Silence It

GOLD COAST, QUEENSLAND – January 28, 2026 – Every week, the equivalent of 680 fully loaded jumbo jets crash with no survivors. That is the global death toll of cardiovascular disease (CVD). In Australia alone, this “crash” kills 45,000 people annually.

While mainstream media ignores this ongoing catastrophe, a potential solution labeled a “breakthrough” by top experts, is being actively suppressed by the very regulators tasked with saving lives.

The Warning They Ignored In October 2022, Prof. Evelyn Tiralongo, then-Chairperson of the TGA Advisory Committee on Complementary Medicines, reviewed the data for Cavadex, a new therapy developed by heart disease survivor Kyle Hodgetts.

Her conclusion was stark: There was “enough information to present an argument that to not pursue it would be negligent”.

She was not alone. The late Prof. Laurie Howes, one of Australia’s most respected cardiologists, titled his correspondence on the matter “CAVADEX BLITZKRIEG,” rallying support from the country’s top specialists. A/Prof Karam Kostner, Director of Cardiology at Mater Brisbane, described the results as “sensational stuff” and stated he was “astounded that nobody else had seriously followed it up”.

The Evidence: Reversing the “Impossible”
Despite this high-level expert consensus, the TGA has not pursued the therapy. Instead, they have moved to restrict it.
Cavadex, a formulation of 2-hydroxypropyl-β-cyclodextrin, targets the root cause of heart disease: arterial plaque and cholesterol crystals. While standard care manages symptoms, Cavadex has demonstrated what mainstream cardiology often deems impossible:

● Reversal of Calcium Scores: Peer-reviewed case series show Coronary Artery Calcium (CAC) scores plummeting by 20–68%.

● Clearer Arteries: CT Angiography has demonstrated critical stenoses reducing from 70–90% blockage down to mild or non-obstructive levels (e.g., from 82% to 27%).

● Clinical Recovery: Hundreds of patients report near-complete resolution of angina, shortness of breath, and claudication.

Regulation Weaponized Following the death of Prof. Howes, the momentum he built was met with regulatory hostility rather than scientific inquiry.

Instead of investigating a therapy that could save 45,000 Australian lives a year, the TGA (which receives 93% of its funding from pharmaceutical industry fees) has focused on silencing the discovery.

● The TGA has issued demand letters forcing the removal of therapeutic claims.

● They have levied fines of over $80,000 against Hodgetts.

● They have restricted how Australians can learn about this low-risk option.

A Failure of Public Duty “One real plane crash makes global headlines for weeks,” says Hodgetts. “Yet the equivalent of Australia’s entire population dies from CVD every year while the media stays silent.”

The TGA’s own advisory chair warned that failing to act would be negligent. The TGA has failed to act.

We demand answers from the TGA, the Health Minister, and the Media:
1. Why was the TGA Advisory Chair’s warning of negligence ignored?

2. Why is enforcement focused on silencing promotion rather than investigating the clinical evidence of reversal?

3. Why are the multi-billion dollar statin and PCSK9 markets protected while a low-cost, effective therapy is fined and suppressed?

Cavadex is not a danger; it is hope. And hope should never be censored.

Media Contact & Access to Evidence:
For interviews, the full October 24, 2022 emails from Prof. Laurie Howes, published papers, CAC regression imaging, CT angiograms, patient testimonies, or clinician statements, contact:
Kyle Hodgetts Cholrem Pty Ltd
Email: [email protected]
Website: www.cholrem.com | www.cavadex.com